JP2024538615A5 - - Google Patents

Info

Publication number
JP2024538615A5
JP2024538615A5 JP2024519447A JP2024519447A JP2024538615A5 JP 2024538615 A5 JP2024538615 A5 JP 2024538615A5 JP 2024519447 A JP2024519447 A JP 2024519447A JP 2024519447 A JP2024519447 A JP 2024519447A JP 2024538615 A5 JP2024538615 A5 JP 2024538615A5
Authority
JP
Japan
Prior art keywords
composition
conjugate
tau
administration
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538615A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077279 external-priority patent/WO2023056369A1/en
Publication of JP2024538615A publication Critical patent/JP2024538615A/ja
Publication of JP2024538615A5 publication Critical patent/JP2024538615A5/ja
Pending legal-status Critical Current

Links

JP2024519447A 2021-09-29 2022-09-29 タウホスホペプチドコンジュゲートの安全な投与の方法 Pending JP2024538615A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261793P 2021-09-29 2021-09-29
US63/261,793 2021-09-29
PCT/US2022/077279 WO2023056369A1 (en) 2021-09-29 2022-09-29 Method of safe administration of tau phosphopeptide conjugate

Publications (2)

Publication Number Publication Date
JP2024538615A JP2024538615A (ja) 2024-10-23
JP2024538615A5 true JP2024538615A5 (enExample) 2025-10-09

Family

ID=85783654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519447A Pending JP2024538615A (ja) 2021-09-29 2022-09-29 タウホスホペプチドコンジュゲートの安全な投与の方法

Country Status (9)

Country Link
US (1) US20250049900A1 (enExample)
EP (1) EP4408864A4 (enExample)
JP (1) JP2024538615A (enExample)
KR (1) KR20240082368A (enExample)
CN (1) CN118613496A (enExample)
AU (1) AU2022356435A1 (enExample)
CA (1) CA3233247A1 (enExample)
MX (1) MX2024003775A (enExample)
WO (1) WO2023056369A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500326A (ja) * 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
CN111787942B (zh) * 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
JOP20210284A1 (ar) * 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو

Similar Documents

Publication Publication Date Title
AU2011200170C1 (en) Alzheimer's disease treatment method
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
AU2009257170B2 (en) Compounds for treating symptoms associated with Parkinson's disease
CN102596236B (zh) 抗原性Tau肽及其用途
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
CN101384279B (zh) 抗淀粉样蛋白免疫原性组合物、方法和用途
US8828942B2 (en) Means for treating synucleinopathies
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
KR20050118669A (ko) 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
US20100028353A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JP2023541669A5 (enExample)
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
EP2659906A1 (en) Compositions
EP2659907A1 (en) Compositions
CN117751132A (zh) 用于治疗阿尔兹海默氏病的tau疫苗
EP2659908A1 (en) Compositions
JP2024538615A5 (enExample)
EP0597838A1 (en) Vaccine compositions
CN104507966B (zh) 基于补体组分c5a的疫苗
US20240358806A1 (en) Methods for the prevention and treatment of synucleinopathies
JP2024532787A5 (enExample)
CN119894531A (zh) Tau肽免疫原构建体
CN121646476A (zh) 用于治疗淀粉样变性的疫苗
JP2023508777A (ja) インターロイキン－６に対して指向される免疫応答を誘導するための免疫原性複合体
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease